Sign in
Taking people in United StatesNo phase

Artisse device for wide-neck brain aneurysms at artery branch points

Tests the Artisse device in adults with wide-neck brain aneurysms, ruptured or not.

Key facts

Who runs it
Medtronic Neurovascular Clinical Affairs
Where
Albany, Boston, Buffalo, Camden, Charlotte, Chicago, Cleveland, Englewood, Greenville, Indianapolis, Iowa City, Jacksonville, Los Angeles, Memphis, Morgantown, New Haven, New York, Oklahoma City, Park Ridge, Philadelphia, Pittsburgh, Salt Lake City, Stony Brook, and Tampa, United StatesSee the 25 sites
Trial code
Registry title
The Artisse™ Intrasaccular Device is Indicated for the Treatment of Wide-neck Bifurcating Intracranial Aneurysms (IAs).
Status
Recruiting
People taking part
300 people, planned
Started
16 Apr 2024
Expected to end
Feb 2032
Type of study
Interventional
Treatments tested
  • Artisse™ Intrasaccular Device
Record updated
9 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with one wide-neck brain aneurysm at a vessel branch point, burst or not burst, to be treated with the Artisse™ Intrasaccular Device.

Age
18-75 years
Sex
All sexes
Disease stage
A single saccular (sac-shaped) brain aneurysm at a branching point, needing treatment. Neck size ≥ 4 mm and/or dome-to-neck ratio of ≥ 1 and < 2. If it burst within the last 30-days, Hunt and Hess Grade I or II and stable. At least one risk factor for rupture. The doctor has already chosen treatment through the blood vessels.
Earlier treatment
The target aneurysm must not have been treated before with other devices, such as coils. Another aneurysm treated before must have been stable for the past 90 days.

Main reasons for not taking part

  • Planned need for another implant device besides the Artisse™ device, or a stent in the parent artery
  • Disability score mRS > 2 before the procedure or before the rupture
  • Bleeding in the brain from another source within 90 days
  • Pregnancy, or plans to become pregnant during the 1 year follow-up
  • Blood thinners that cannot be stopped for at least 7 days after the procedure, or kidney failure blocking angiography (unless on dialysis)

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Subject or subject's Legally Authorized Representative (LAR) has provided written informed consent using the Institutional Review Board/Ethics Committee (IRB/EC) approved Informed Consent Form (ICF). Health Insurance Portability and Accountability Act (HIPAA)/data protection authorization has been provided and signed by the subject or subject's LAR
  • Subject is 18-75 years of age at the time of consent
  • Subject has a single unruptured or ruptured IA requiring treatment. If the patient has an additional IA, the additional IA must not be deemed to require treatment within 1-year of the index procedure
  • The target aneurysm must have the following characteristics:; Saccular morphology; Located at a bifurcation in the anterior or posterior circulation; Aneurysm Width appropriate for treatment with the Artisse™ Intrasaccular Device for device sizingper the Instructions for Use; Wide-necked, defined as neck size ≥ 4 mm and/or a dome-to-neck ratio of ≥ 1 and < 2
  • If the target aneurysm was acutely ruptured, subject must be neurologically stable with Hunt and Hess Grade of I or II; Ruptured IA is defined as showing evidence of SAH attributed to the target aneurysm within the last 30-days (using computed tomography (CT), magnetic resonance imaging (MRI), or lumbar puncture (LP).)
  • Subject is able to comply with all aspects of the Clinical Investigation Plan (CIP) requirements (e.g., screening, evaluation, treatment, and the post-procedure follow-up schedule)
  • Subject meets one or more risk factors for IA rupture, such as age, hypertension, cigarette smoking, use of sympathomimetic drugs, Japanese or Finnish ancestry, history of prior aneurysmal subarachnoid hemorrhage (aSAH), familial intracranial aneurysms or SAH, clinical or radiological mass effect, reduced quality of life due to fear of rupture, IA size, location, and morphology, documented growth of IA on serial imaging (or enhanced aneurysm walls on contrast), presence of multiple IAs, and presence of concurrent pathology
  • Treating physician has already selected the subject for endovascular treatment of the target aneurysm after considering risk-benefit of clipping vs endovascular treatment
  • If the subject has an additional IA that was treated previously, the additional IA must have been clinically stable in the past 90 days (i.e. without ongoing adverse events related to the previous treatment)

Who cannot take part

  • During treatment planning, it is determined that subject may need an adjunctive implant device in addition to the Artisse™ Intrasaccular Device. (Subjects who need unplanned adjunctive implant devices are not excluded.)
  • Subject's target aneurysm was previously treated with other devices/implants (e.g., coils) or parent artery has a stent or other obstruction that could interfere with the correct placement of the Artisse™ Intrasaccular Device
  • Subject has anatomy or physiology considered unsuitable (e.g., vessel anomaly or disease) for endovascular treatment with the Artisse™ Intrasaccular Device by the treating physician
  • Subject has a mRS score > 2 (i.e., mRS scores of 3 to 5) prior to procedure (in case of unruptured IA) or prior to rupture (in case of ruptured IA)
  • Subject is enrolled in another device or drug study in which participation could confound study results
  • Subject has a known active systemic bacterial infection
  • Subject has an SAH from a non-target aneurysm or any other intracranial hemorrhage within 90 days
  • The treating physician determines that the health of the subject or the validity of the study outcomes (e.g., high risk of neurologic events, conditions that may increase the chance of stroke) may be compromised by the subject's enrollment
  • Subject has a known hypersensitivity, which cannot be medically treated, to any component of the study device, procedural materials, or medications commonly used during the procedure
  • Subject has acute or chronic renal failure (unless on dialysis) that would prevent them from undergoing digital subtraction angiography (DSA)
  • Subject has a life expectancy of less than 5 years due to an illness or condition other than the index IA
  • Subject, of child-bearing potential, is pregnant (confirmed with a positive pregnancy test) or plans to become pregnant during the 1 year follow up period after the index procedure
  • Subject is taking anticoagulants (e.g., warfarin) that cannot be discontinued for a minimum of 7 days post-procedure or have a known blood dyscrasia, coagulopathy, or hemoglobinopathy

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

  • Albany Medical CenterAlbany, United StatesContact: Alexandra Paul, MDTaking people
  • Massachusetts General HospitalBoston, United StatesContact: Shayna HollanderTaking people
  • Buffalo General Medical CenterBuffalo, United StatesContact: Adnan Siddiqui, MDTaking people
  • Cooper University HealthCamden, United StatesContact: Thuy Van CaoTaking people
  • Novant Health Brain and Spine SurgeryCharlotte, United StatesContact: Ziad Hage, MDTaking people
  • University of ChicagoChicago, United StatesContact: Khalid TradTaking people
  • Cleveland Clinic FoundationCleveland, United StatesContact: Heidi PoppendeckTaking people
  • Swedish Medical CenterEnglewood, United StatesContact: Ashley ThompsonTaking people
  • Prisma HealthGreenville, United StatesContact: Mohammad Chaudry, MDTaking people
  • Ascension Saint Vincent Hospital - IndianapolisIndianapolis, United StatesContact: Luke WatkinsTaking people
  • University of Iowa Hospitals and ClinicsIowa City, United StatesContact: Heena OlaldeTaking people
  • Baptist Medical Center JacksonvilleJacksonville, United StatesContact: Smitha Gubbi, MDTaking people
  • USC Keck School of MedicineLos Angeles, United StatesContact: Kelly HuTaking people
  • Semmes Murphy ClinicMemphis, United StatesContact: Wendell BarnettTaking people
  • West Virginia UniversityMorgantown, United StatesContact: Jennifer DomicoTaking people
  • Yale New Haven HospitalNew Haven, United StatesContact: Lindsey FraczkiewiczTaking people
  • The Mount Sinai HospitalNew York, United StatesContact: Johanna Fifi, MDTaking people
  • Oklahoma University Medical CenterOklahoma City, United StatesContact: Katarzyna Zyla-JacksonTaking people
  • Advocate Lutheran General HospitalPark Ridge, United StatesContact: Victor ArroyoTaking people
  • Hospital of the University of PennsylvaniaPhiladelphia, United StatesContact: Christopher BoivinTaking people
  • Thomas Jefferson University HospitalPhiladelphia, United StatesContact: Nico AgostiTaking people
  • UPMC PresbyterianPittsburgh, United StatesContact: Lauren PuccioTaking people
  • University of Utah HospitalSalt Lake City, United StatesContact: Ramesh Grandhi, MDTaking people
  • Stony Brook University HospitalStony Brook, United StatesContact: Marlene BaumeisterTaking people
  • Tampa General HospitalTampa, United StatesContact: Muni Sai BachalakuriTaking people

About the trial

What the trial wants to find out

The purpose of this study is to assess the safety and effectiveness of the Artisse™ Intrasaccular Device in the treatment of unruptured and ruptured wide-neck bifurcating intracranial aneurysms.

The group in the trial

  • Artisse™ Intrasaccular DeviceTreatment being tested

    Study subjects with an unruptured or ruptured wide-neck bifurcating intracranial aneurysm will be treated by endovascular implantation of the Artisse™ Intrasaccular Device.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Artisse™ Intrasaccular Device IDE
Plain-language title
Artisse device for wide-neck brain aneurysms at artery branch pointsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT02998229, who can take part
Record updated
9 October 2026